Why Pro Medicus (ASX: PME) Is Betting Big on Echo IQ’s AI Heart Technology

Key Highlights

• Echo IQ secures up to A$20 million strategic investment from Pro Medicus

• Pro Medicus plans to become a US reseller of EchoSolv, subject to final agreements

• Partnership builds on Echo IQ’s recent collaborations with Mayo Clinic and Mount Sinai

• Echo IQ shares surged 35.89% to A$1.685, valuing the company at more than A$1 billion

Artificial intelligence is rapidly changing healthcare, but few small companies manage to attract the backing of one of Australia’s most respected medical technology businesses.

That changed on Thursday when Echo IQ (ASX: EIQ) announced a binding Heads of Agreement with Pro Medicus (ASX: PME), combining a potential A$20 million investment with a commercial partnership aimed squarely at the United States healthcare market.

For Echo IQ, the agreement is about far more than funding. It provides both financial backing and access to one of the world’s largest medical imaging networks at a time when hospitals are increasingly looking to artificial intelligence to improve clinical decision making.

The proposed deal includes an immediate A$10 million investment through secured convertible notes, with a further A$10 million available if Echo IQ receives US Food and Drug Administration clearance for its EchoSolv HF heart failure algorithm.

Subject to definitive agreements, Pro Medicus will also become an official reseller of Echo IQ’s EchoSolv platform across the United States.

That combination could significantly shorten what is often a lengthy and expensive path into American hospitals.

The US healthcare market is notoriously difficult for emerging medical technology companies to penetrate. Even promising software can spend years building credibility, sales teams and hospital relationships before generating meaningful revenue.

Echo IQ is attempting to bypass much of that challenge.

Pro Medicus’ Visage imaging platform is already embedded across leading US hospitals and academic medical centres. By plugging into that existing commercial infrastructure, Echo IQ gains access to customers that would otherwise take years to reach.

The partnership also arrives after several months of operational momentum for the company.

Earlier this year, Echo IQ expanded its collaboration with the Mayo Clinic to validate its EchoSolv HF heart failure algorithm, while Mount Sinai Health System in New York deployed the company’s EchoSolv AS platform to assist clinicians in identifying severe aortic stenosis.

The latest agreement adds another layer of commercial validation.

Echo IQ Chief Executive Officer Dustin Haines said the agreement represents a defining moment for the company.

“The execution of this binding Heads of Agreement with Pro Medicus represents a transformational milestone for Echo IQ and a significant validation of both our technology and long-term commercial strategy. Pro Medicus’ decision to pursue both a strategic investment and commercial partnership with Echo IQ reflects the growing clinical relevance of artificial intelligence in cardiovascular care.”

“Importantly, this proposed partnership extends far beyond the investment itself. Through Pro Medicus, we have the opportunity to leverage an established healthcare platform, trusted customer relationships and a highly experienced commercial organisation with deep penetration into the US healthcare market. We believe this creates a compelling pathway to accelerate awareness, adoption and commercialisation of EchoSolv across a broad range of healthcare providers.”

The market welcomed the announcement.

Echo IQ shares climbed 35.89% to A$1.685 during morning trade, extending a remarkable 586.7% gain over the past year. The company now carries a market capitalisation of approximately A$1.02 billion after once being regarded as a micro-cap healthcare developer.

Source: MarketIndex 

Even so, several milestones remain before the partnership reaches its full potential.

The second A$10 million investment depends on FDA clearance for EchoSolv HF, while the commercial reseller arrangement remains subject to definitive legal documentation over the coming weeks.

The funding structure also comes with convertible notes carrying a 12.5% annual interest rate, compounded daily, alongside potential shareholder dilution if the securities convert into equity.

Despite those considerations, the agreement highlights a broader trend emerging across global healthcare.

Hospitals are increasingly moving beyond general-purpose artificial intelligence toward specialised clinical tools capable of identifying diseases earlier and supporting physician decision making. Cardiovascular disease remains one of the world’s leading causes of death, making accurate diagnostic software an area of growing commercial interest.

For Pro Medicus, backing Echo IQ represents an investment in that future. For Echo IQ, it may prove to be the partnership that transforms years of clinical development into large-scale commercial adoption.

Source: Echo IQ ASX announcement dated 25 June 2026, Pro Medicus partnership announcement, ASX market data, company filings, Mayo Clinic collaboration announcements and Mount Sinai Health System deployment updates.